1. Home
  2. SOHU vs TTRX Comparison

SOHU vs TTRX Comparison

Compare SOHU & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

HOLD

Current Price

$12.83

Market Cap

337.1M

Sector

Technology

ML Signal

HOLD

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$15.30

Market Cap

298.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOHU
TTRX
Founded
1996
2015
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
337.1M
298.8M
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
SOHU
TTRX
Price
$12.83
$15.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$20.00
$8.00
AVG Volume (30 Days)
61.1K
113.8K
Earning Date
05-18-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.61
N/A
Revenue Next Year
$3.78
N/A
P/E Ratio
$1.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.61
$2.57
52 Week High
$17.30
$16.45

Technical Indicators

Market Signals
Indicator
SOHU
TTRX
Relative Strength Index (RSI) 33.75 73.81
Support Level $11.61 $3.68
Resistance Level $13.71 N/A
Average True Range (ATR) 0.49 1.42
MACD -0.13 0.33
Stochastic Oscillator 21.92 81.74

Price Performance

Historical Comparison
SOHU
TTRX

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: